March 2023

New CLTI treatment limits amputations | Mediterranean diet's many benefits | More bad news for troubled devices ()
Cardiologist salaries on the rise | FDA approves Abbott's new valve | Transradial PCI | More from the last week ()
Abbott's new FDA approval | Transradial PCI & patient outcomes | Cardiologists support new AED legislation ()
Early mortality vs. occasional walking | ‘Obesity paradox’ nullified | Ionizing radiation and heart disease ()
Incidental genetic insights | Accurate electrocardiogram AI | Healthcare’s ‘modern gangsters’ ()
Transcatheter LAAO consensus | Infections and CVD | Pediatric LDL drug | more ()
Cardiologist salaries continue to rise | Diabetes, coronary heart disease increase risk of long COVID ()
A new recall | $1.1B in industry payments | OBLs & ASCs | Reimbursement challenges | More from the last week ()
Heart Rhythm Highlights: The next big EP technology trend | Teen's death blamed on defibrillator issue ()
AI's impact on echocardiography | FDA announces blood thinner recall | Heart tissue heads to space ()
News Alert: Blood thinner recalled due to potential cancer risk ()
Care Delivery Highlights: TAVR vs. SAVR | Cardiologists warn the White House | Treating PAD & CLI ()
The rise of outpatient OBLs and ASCs | CVRx, Abbott share new data at THT 2023 | Key PULSED-AF details ()
Reimbursement challenges in cardiology | Preparing for the migration of procedures to OBLs and ASCs ()
Imaging Highlights: Heart inflammation & long COVID | Cardiac POCUS in pediatric patients ()
Cardiologists received $1.1B in industry payments in 6 years | ACC.23 in photos | AED at center of lawsuit ()
Estrogen & heart rhythm issues | Troubled heart devices recalled again | Startup raises $25M ()
Tricuspid TEER | A new recall for heart devices | Next-gen TAVR valve delivers | More from the last week ()
News Alert: FDA announces new Class I recall of troubled heart devices ()
Heart Health Highlights: Daily marijuana use & CAD | Artificial sweetener linked to multiple risks ()
ACC looking closer at the business side of cardiology | A key approval for Medtronic | Celebrating good ethics ()
TAVR Highlights: 10 reasons to still consider SAVR | Data mining helps hospitals bring in new patients ()
Mediterranean diet & CVD in women | Exploring the CLEAR Outcomes trial | Next-gen TAVR valve delivers ()
Interventional Cardiology Highlights: New ACC/AHA/SCAI recommendations | Intravascular imaging during PCI ()
Children with autism face higher risk of diabetes, heart disease | PFA & bronchial damage | A new IVL catheter ()
Vascular & Endovascular Highlights: PAD patients at risk | Intravascular imaging during PCI | CLI treatments ()
TRILUMINATE may pave way for FDA clearance of tricuspid valve clip | Fasting improves cardiac COVID outcomes ()
TRILUMINATE trial to pave way for FDA clearance of tricuspid valve clip | Fasting improves cardiac COVID outcomes ()
Structural Heart Disease Highlights: 10 reasons heart teams may consider SAVR over TAVR | ACC late-breakers ()
Key takeaways from ACC.23 | How to anticoagulate COVID patients | Links to all the ACC late-breaking trials ()
Heart Failure Highlights: The limited the value of dapagliflozin & empagliflozin | FDA rules on omecamtiv mecarbil ()
Heart inflammation seen in some patients 2 months after vaccination | Early menopause & TAVR outcomes ()
Cardiologist violently attacked | Keto-like diets & heart disease | ACC.23 | More from the last week ()
Cardiologists send warning to the White House | ACC.23 seen as a return to normalcy | SGLT2 inhibitors & HF ()
Keto diets linked to high cholesterol, CVD | New ACC president shares his vision | Cardiologist violently attacked ()
Economics highlights: Private equity investments in cardiology | GE Healthcare & Abbott make big moves ()
More late-breaking studies from ACC | Unheeded statin recommendations | Infertility and heart disease ()
In-person coverage from ACC.23 in New Orleans | Cardiac tamponade during AFib ablation ()
Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair & statins ()
A warning from the FDA | Marijuana use & CAD | Choosing SAVR over TAVR | More from the last week! ()
10 reasons to consider SAVR over TAVR | Cardiac POCUS in children | CLI treatment still evolving ()
February's Most Popular Stories: Coronary IVL | Private equity & cardiology | ChatGPT | ICE & TEE | Much more ()
FDA clears 2 new solutions, rules on omecamtiv mecarbil for HFrEF | AI model uses DNA to predict AFib, HF ()